Teglicar HCl | CAS#908566-80-3

MedKoo Cat#: 412711 | Name: Teglicar HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Teglicar, also known as ST1326, is a selective and reversible inhibitor of liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). Teglicar reduces ketogenesis and glucose production, decreases gluconeogenesis and improves glucose homeostasis.

Chemical Structure

Teglicar HCl

CAS#908566-80-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 412711

Name: Teglicar HCl

CAS#: 908566-80-3 (HCl)

Chemical Formula: C22H46ClN3O3

Exact Mass: 399.3461

Molecular Weight: 436.08

Elemental Analysis: C, 60.60; H, 10.63; Cl, 8.13; N, 9.64; O, 11.01

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 389.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1130550-29-6 (cation) 250694-07-6 908566-80-3 (HCl)

Synonym

Teglicar; 4-trimethylammonio-TDCAB; ST1326; ST-1326; ST 1326; Teglicar HCl

IUPAC/Chemical Name

(R)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate hydrochloride

InChi Key

YZUSMEACRPRNGS-VEIFNGETSA-N

InChi Code

InChI=1S/C22H45N3O3.ClH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4;/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28);1H/t20-;/m1./s1

SMILES Code

O=C([O-])C[C@@H](NC(NCCCCCCCCCCCCCC)=O)C[N+](C)(C)C.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 436.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Qu Q, Zeng F, Liu X, Wang QJ, Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis. 2016 May 19;7(5):e2226. doi: 10.1038/cddis.2016.132. PMID: 27195673; PMCID: PMC4917665. 2: Pacilli A, Calienni M, Margarucci S, D'Apolito M, Petillo O, Rocchi L, Pasquinelli G, Nicolai R, Koverech A, Calvani M, Peluso G, Montanaro L. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J Natl Cancer Inst. 2013 Apr 3;105(7):489-98. doi: 10.1093/jnci/djt030. Epub 2013 Mar 13. PMID: 23486551. 3: Samudio I, Konopleva M. Targeting leukemia's "fatty tooth". Blood. 2015 Oct 15;126(16):1874-5. doi: 10.1182/blood-2015-08-665125. PMID: 26472736. 4: Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Foà R, Nicolai R, Peluso G, Tafuri A. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood. 2015 Oct 15;126(16):1925-9. doi: 10.1182/blood-2014-12-617498. Epub 2015 Aug 14. PMID: 26276667. 5: Perspicace S, Rufer AC, Thoma R, Mueller F, Hennig M, Ceccarelli S, Schulz- Gasch T, Seelig J. Isothermal titration calorimetry with micelles: Thermodynamics of inhibitor binding to carnitine palmitoyltransferase 2 membrane protein. FEBS Open Bio. 2013 Apr 19;3:204-11. doi: 10.1016/j.fob.2013.04.003. PMID: 23772395; PMCID: PMC3668529. 6: Coccurello R, Caprioli A, Bellantuono S, D'Amato FR, Conti R, Giannessi F, Borsini F, Moles A. Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice. Psychopharmacology (Berl). 2010 May;210(1):85-95. doi: 10.1007/s00213-010-1820-0. Epub 2010 Mar 16. PMID: 20232053. 7: Rufer AC, Thoma R, Benz J, Stihle M, Gsell B, De Roo E, Banner DW, Mueller F, Chomienne O, Hennig M. The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. Structure. 2006 Apr;14(4):713-23. doi: 10.1016/j.str.2006.01.008. PMID: 16615913. 8: Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Tvedt TH, Bruserud Ø, Hatfield KJ. Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity. Cells. 2020 May 7;9(5):1155. doi: 10.3390/cells9051155. PMID: 32392896; PMCID: PMC7290417. 9: Olkkola S, Kovanen S, Roine J, Hänninen ML, Hielm-Björkman A, Kivistö R. Population Genetics and Antimicrobial Susceptibility of Canine Campylobacter Isolates Collected before and after a Raw Feeding Experiment. PLoS One. 2015 Jul 14;10(7):e0132660. doi: 10.1371/journal.pone.0132660. PMID: 26172151; PMCID: PMC4501809. 10: Conti R, Mannucci E, Pessotto P, Tassoni E, Carminati P, Giannessi F, Arduini A. Selective reversible inhibition of liver carnitine palmitoyl- transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes. 2011 Feb;60(2):644-51. doi: 10.2337/db10-0346. PMID: 21270274; PMCID: PMC3028366.